Kura Oncology (KURA)
(Delayed Data from NSDQ)
$8.44 USD
+0.35 (4.33%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $8.44 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KURA 8.44 +0.35(4.33%)
Will KURA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KURA
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Is the Options Market Predicting a Spike in Kura Oncology Stock?
KURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
Other News for KURA
Jefferies Sticks to Its Buy Rating for Kura Oncology (KURA)
KURA's price falls by 3.11% on September 17, though its technical setup remains stable.
Leerink Partners Reaffirms Their Buy Rating on Kura Oncology (KURA)
TD Cowen Sticks to Their Buy Rating for Kura Oncology (KURA)
Bank of America Securities Keeps Their Buy Rating on Kura Oncology (KURA)